Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma

NCT00796445 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00796445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00796445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
December 1, 2008
Completion date
January 27, 2016
Enrollment
1,351 (actual)
Sites
257

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma